Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 956-964

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

By Williams-Herman Debora   Johnson Jeremy   Teng Rujun   Luo Edmund   Davies Michael J.   Kaufman Keith D.   Goldstein Barry J.   Amatruda John M.  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

By Raz Itamar   Chen Yu   Wu Mei   Hussain Shehla   Kaufman Keith D.   Amatruda John M.   Langdon Ronald B.   Stein Peter P.   Alba Maria  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 537-550

Informa Healthcare

Access to resources Recommend Favorite

A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once‐daily injection in patients with well‐controlled type 2 diabetes

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 831-838

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 581-590

John Wiley & Sons Inc

Access to resources Recommend Favorite